Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855864 | 0.79 | TP53 (0.43) | IDO1CYP1A2CYP2A6TAAR1TDP1 | |
| SCHEMBL30028871 | 0.78 | HRH3 (0.41) | IDO1TAAR1AGXTHRH3LMNA | |
| SCHEMBL5672968 | 0.76 | IDO1 (0.48) | IDO1TAAR1AGXTCHRM2LMNA | |
| SCHEMBL29954468 | 0.74 | IDH1 (0.35) | ALDH1A1 | |
| SCHEMBL12374395 | 0.74 | ALDH1A1 (0.50) | TDP1MAPTTP53ALDH1A1MEN1 | |
| SCHEMBL12629117 | 0.74 | PGK1 (0.38) | — | |
| SCHEMBL3890376 | 0.74 | TAAR1 (0.42) | IDO1CYP2A6TAAR1ALDH1A1KDM4E | |
| SCHEMBL11740256 | 0.74 | ESR1 (0.50) | IDO1TAAR1TDP1MAPTALDH1A1 | |
| SCHEMBL1104002 | 0.73 | IDO1 (0.52) | IDO1CYP1A2TAAR1AGXTMAPT | |
| SCHEMBL4403988 | 0.73 | TSHR (0.42) | ACHETP53CA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-111699174-A | Spiro compound used as indoleamine-2, 3-dioxygenase inhibitor | 中国科学院上海有机化学研究所 | 2020-09-22 | — | — | CN | disclosed |
| CN-104271565-B | Amide pyridine derivatives and use thereof | 田边三菱制药株式会社 | 2016-09-28 | — | — | CN | disclosed |
| CN-104271565-A | Amide pyridine derivatives and use thereof | MITSUBISHI TANABE PHARMA CORP | 2015-01-07 | — | — | CN | disclosed |
| US-8927536-B2 | Tetrahydrothiazepine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20140080808-A1 | TETRAHYDROTHIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8492111-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-23 | — | — | US | disclosed |
| US-5606037-A | Processes antineoplastic heteronaphthoquinones | BIOCHEM PHARMA INC. (CA) | 1997-02-25 | — | — | US | disclosed |
| EP-0480204-B1 | Imidazole derivatives, potent and selective antagonists of angiotensin II receptor | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5215994-A | Treating or preventing hypertension or heart failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| US-5210092-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-11 | — | — | US | disclosed |
| EP-0480204-A1 | Imidazole derivatives, potent and selective antagonists of angiotensin II receptor | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991007380-A1 | ARTHROPODICIDES | DUNLENA PTY. LTD. (AU) | 1991-05-30 | — | — | WO | disclosed |
| US-4857647-A | 4-amino-5-chloro-2-methoxy-n-(6-(1-azabicyclo[3,2,1]octyl)benzamide | BEECHAM GROUP P.L.C. (GB) | 1989-08-15 | — | — | US | disclosed |
| US-4697019-A | Azabicyclo compounds, useful as intermediates | BEECHAM GROUP P.L.C. (GB) | 1987-09-29 | — | — | US | disclosed |
| US-4612319-A | Bridged quinolizidinylbenzamides, compositions containing them and methods for their use | BEECHAM GROUP P.L.C. (GB) | 1986-09-16 | — | — | US | disclosed |
| EP-0094742-A2 | Substituted azabicyclo compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | NAT1, INMT, ARSA | IDO1 113/4885CYP1A2 28/4885CYP2A6 38/4885 |
| US-20140080808-A1 | TETRAHYDROTHIAZEPINE DERIVATIVE | HSD11B1, HSD11B2, HSD3B1 | IDO1 1196/4885CYP1A2 65/4885CYP2A6 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.